Summit Wealth Group’s DexCom DXCM Stock Holding History

Summit Wealth Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,145	Closed	–	–	133
2023 Q1	$0	Buy	+21,145	New	+$2.37M	﹤0.01%	185

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Summit Wealth Group's DXCM Position: Q2 2023 in Review

Summit Wealth Group sold out of DexCom (DXCM) in Q2 2023, closing a stake of 21,145 shares.

Summit Wealth Group first reported a position in DXCM in Q1 2023 and held it in 1 quarter. The position peaked at $0 in Q1 2023. 954 funds tracked by Wall St. Rank hold DXCM as of Q2 2023.

Summit Wealth Group reported no remaining DexCom position as of Q2 2023 after selling out during the quarter.
Summit Wealth Group sold 21,145 DexCom shares in Q2 2023.
Summit Wealth Group first reported a position in DexCom in Q1 2023 and held it in 1 quarter.
Summit Wealth Group's DexCom position peaked at $0 in Q1 2023.
954 funds tracked by Wall St. Rank held DexCom as of Q2 2023.

Based on Summit Wealth Group's 13F filing for Q2 2023, filed 26 Jul 2023.